Professional Documents
Culture Documents
penurunan setelah pemakaian lestaurtinib. Namun, diperlukan evaluasi dan penelitian lebih lanjut
mengenai penggunaan agen lestaurtinib, dengan kombinaso dengan penggunaan kemoterapi
sitotoksik ataupun dengan agen terapi target lainnya (Burnett & Knapper, 2007; Knapper, 2006).
Daftar Pustaka
Bakta, I.M. 2003. Hematologi Klinik Ringkas. Jakarta: EGC. p.137-144.
Burnett, A.K. Knapper, S. 2007. Targeting Treatment in AML. American Society of Hematology.
p.429-434.
Knapper, S. et al. 2006. A Phase 2 Trial of The FLT3 Inhibitor Lestaurtinib (CEP701) as FirstLine Treatment for Older Patients with Acute Myeloid Leukemia Not Considered Fit for
Intensive Chemotherapy. The American Society of Hematology, vol.108, no.10: 32623270.
Quints-Cardama, A. Cortes, J. 2006. Kinase Inhibitors in Chronic Myelogenous Leukemia.
Clinical Advances in Hematology & Oncology, vol. 4, no. 5:365-374.
Rogers, B.B. 2012. Targeted Therapies in the Management of Leukemia and Lymphoma.
Oncology, vol. 26;2-16.